Skip to main content
Premium Trial:

Request an Annual Quote

Centogene Inks Drug Discovery, Development Deal With Chiesi

NEW YORK (GenomeWeb) — Centogene announced on Monday that it has formed a drug discovery and development partnership with Italian drug developer Chiesi.

Under the terms of the deal, Hamburg, Germany-based Centogene will perform a European epidemiological study focused on the prevalence of alpha mannosidosis (AM) — a rare genetic lysosomal storage disorder caused by mutations in the MAN2B1 gene and a core indication for Chiesi. Centogene said it will collect samples from individuals suspected to have AM using its CentoCard dried blood spot collection kit, which it will use to fully sequence MAN2B1 to identify disease-causing mutations.

"Our joint collaboration underpins our globally strong position to speed up the early identification of patients with rare genetic diseases," Centogene CEO Arndt Rolfs said in a statement. "We welcome the opportunity to work with Chiesi … and provide valuable epidemiological and prevalent insights into this devastating condition."

Earlier this year, Centogene — which opened a Boston office in late 2017 — formed a collaboration with Evotec to discover and develop drugs for rare hereditary metabolic diseases and began working with Aldeyra Therapeutics to identify patients with Sjögren-Larsson Syndrome.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.